학술논문
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab
Document Type
Article
Author
Source
In: Cancer Immunology Research . (Cancer Immunology Research, October 2022, 10(10):1175-1189)
Subject
Language
English
ISSN
23266074
23266066
23266066